- Dyskeratosis congenita is a rare inherited disorder characterised by defective telomere maintenance, leading to premature cellular ageing and progressive organ dysfunction. It belongs to the group of telomeropathies, conditions in which mutations impair the ability of telomerase or telomere‑associated proteins to preserve chromosome ends. As telomeres shorten more rapidly than normal, cells lose their capacity to divide, repair damage and maintain tissue integrity. This accelerated telomere attrition results in early onset of bone‑marrow failure, mucocutaneous abnormalities and increased susceptibility to pulmonary, hepatic and gastrointestinal disease. Dyskeratosis congenita therefore provides a powerful model for understanding how telomere biology shapes human ageing and tissue homeostasis.
- At the molecular level, dyskeratosis congenita arises from mutations in genes essential for telomerase function or telomere protection. The most frequently affected genes include DKC1, which encodes dyskerin, a protein required for stabilising the telomerase RNA component; TERT, the catalytic subunit of telomerase; and TERC, the RNA template used for telomere extension. Mutations in telomere‑binding proteins such as POT1 also contribute to the disorder by weakening telomere protection and accelerating DNA damage signalling. These genetic defects compromise telomerase activity, resulting in critically short telomeres that trigger cellular senescence and apoptosis, particularly in tissues with high turnover such as the bone marrow, skin and mucosal epithelium.
- Clinically, dyskeratosis congenita presents with a classic triad of mucocutaneous features: abnormal skin pigmentation, nail dystrophy and oral leukoplakia. However, the disease extends far beyond these visible signs. Progressive bone‑marrow failure is one of the most serious complications, often manifesting as aplastic anaemia during childhood or early adulthood. Patients may also develop pulmonary fibrosis, liver cirrhosis, gastrointestinal strictures and increased cancer risk, reflecting the systemic consequences of impaired telomere maintenance. The severity and age of onset vary widely depending on the specific mutation and the degree of telomere shortening, with some individuals presenting early in life and others developing symptoms later.
- Dyskeratosis congenita also illustrates how telomere dysfunction drives premature ageing. Tissues dependent on continuous cell renewal gradually lose regenerative capacity, leading to early organ failure and chronic inflammation. Elevated DNA‑damage signalling and persistent activation of senescence pathways contribute to tissue degeneration and fibrosis. The disorder shares mechanistic overlap with other progeroid conditions, reinforcing the central role of telomere biology in determining the pace of biological ageing. Research into dyskeratosis congenita has therefore been instrumental in revealing how telomere length influences longevity, stem‑cell function and susceptibility to age‑related disease.
- Management of dyskeratosis congenita focuses on monitoring organ function, treating bone‑marrow failure and preventing complications. Haematopoietic stem‑cell transplantation remains the only curative option for severe marrow failure, although it carries significant risks due to underlying telomere defects. Supportive care includes surveillance for pulmonary fibrosis, liver disease and malignancies. Advances in telomere biology continue to inform potential therapeutic strategies, including approaches aimed at enhancing telomerase activity or protecting telomere structure.
- In summary, dyskeratosis congenita is a telomere‑maintenance disorder that causes premature cellular ageing and multisystem disease. It arises from mutations in telomerase components or telomere‑binding proteins, leading to accelerated telomere shortening, genomic instability and early tissue failure. Understanding this condition provides crucial insight into the molecular foundations of ageing, stem‑cell exhaustion and organ degeneration.
